<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34131277</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0307</ISSN><JournalIssue CitedMedium="Internet"><Volume>101</Volume><Issue>10</Issue><PubDate><Year>2021</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Laboratory investigation; a journal of technical methods and pathology</Title><ISOAbbreviation>Lab Invest</ISOAbbreviation></Journal><ArticleTitle>Establishment of chemically oligomerizable TAR DNA-binding protein-43 which mimics amyotrophic lateral sclerosis pathology in mammalian cells.</ArticleTitle><Pagination><StartPage>1331</StartPage><EndPage>1340</EndPage><MedlinePgn>1331-1340</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41374-021-00623-4</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0023-6837(22)00396-8</ELocationID><Abstract><AbstractText>One of the pathological hallmarks of amyotrophic lateral sclerosis (ALS) is mislocalized, cytosolic aggregation of TAR DNA-Binding Protein-43 (TDP-43). Not only TDP-43 per se is a causative gene of ALS but also mislocalization and aggregation of TDP-43 seems to be a common pathological change in both sporadic and familial ALS. The mechanism how nuclear TDP-43 transforms into cytosolic aggregates remains elusive, but recent studies using optogenetics have proposed that aberrant liquid-liquid phase separation (LLPS) of TDP-43 links to the aggregation process, leading to cytosolic distribution. Although LLPS plays an important role in the aggregate formation, there are still several technical problems in the optogenetic technique to be solved to progress further in vivo study. Here we report a chemically oligomerizable TDP-43 system. Oligomerization of TDP-43 was achieved by a small compound AP20187, and oligomerized TDP-43 underwent aggregate formation, followed by cytosolic mislocalization and induction of cell toxicity. The mislocalized TDP-43 co-aggregated with wt-TDP-43, Fused-in-sarcoma (FUS), TIA1 and sequestosome 1 (SQSTM1)/p62, mimicking ALS pathology. The chemically oligomerizable TDP-43 also revealed the roles of the N-terminal domain, RNA-recognition motif, nuclear export signal and low complexity domain in the aggregate formation and mislocalization of TDP-43. The aggregate-prone properties of TDP-43 were enhanced by a familial ALS-causative mutation. In conclusion, the chemically oligomerizable TDP-43 system could be useful to study the mechanisms underlying the droplet-aggregation phase transition and cytosolic mislocalization of TDP-43 in ALS and further study in vivo.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s), under exclusive licence to United States and Canadian Academy of Pathology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yamanaka</LastName><ForeName>Yoshiaki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Molecular Pathology, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo, 160-8402, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyagi</LastName><ForeName>Tamami</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Molecular Pathology, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo, 160-8402, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harada</LastName><ForeName>Yuichiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Molecular Pathology, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo, 160-8402, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuroda</LastName><ForeName>Masahiko</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7052-4289</Identifier><AffiliationInfo><Affiliation>Department of Molecular Pathology, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo, 160-8402, Japan. kuroda@tokyo-med.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanekura</LastName><ForeName>Kohsuke</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-2901-9595</Identifier><AffiliationInfo><Affiliation>Department of Molecular Pathology, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo, 160-8402, Japan. kanekura@tokyo-med.ac.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Lab Invest</MedlineTA><NlmUniqueID>0376617</NlmUniqueID><ISSNLinking>0023-6837</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="Y">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>5</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>40</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34131277</ArticleId><ArticleId IdType="doi">10.1038/s41374-021-00623-4</ArticleId><ArticleId IdType="pii">S0023-6837(22)00396-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Logroscino G, Piccininni M, Marin B, Nichols E, Abd-Allah F, Abdelalim A, et al. Global, regional, and national burden of motor neuron diseases 1990&#x2013;2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17:1083&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30404-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurel C, Dangoumau A, Marouillat S, Brulard C, Chami A, Hergesheimer R, et al. Causative Genes in Amyotrophic Lateral Sclerosis and Protein Degradation Pathways: a Link to Neurodegeneration. Mol. Neurobiol. 2018;55:6480&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">29322304</ArticleId><ArticleId IdType="doi">10.1007/s12035-017-0856-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319:1668&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">18309045</ArticleId><ArticleId IdType="pmc">7116650</ArticleId><ArticleId IdType="doi">10.1126/science.1154584</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId><ArticleId IdType="doi">10.1126/science.1134108</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 2006;351:602&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">17084815</ArticleId><ArticleId IdType="doi">10.1016/j.bbrc.2006.10.093</ArticleId></ArticleIdList></Reference><Reference><Citation>Morera AA, Ahmed NS, Schwartz JC. TDP-43 regulates transcription at protein-coding genes and Alu retrotransposons. Biochim Biophys Acta Gene Regul Mech. 2019;1862:194434.</Citation><ArticleIdList><ArticleId IdType="pubmed">31655156</ArticleId><ArticleId IdType="pmc">6899060</ArticleId><ArticleId IdType="doi">10.1016/j.bbagrm.2019.194434</ArticleId></ArticleIdList></Reference><Reference><Citation>Afroz T, Hock EM, Ernst P, Foglieni C, Jambeau M, Gilhespy LAB, et al. Functional and dynamic polymerization of the ALS-linked protein TDP-43 antagonizes its pathologic aggregation. Nat Commun. 2017;8:45.</Citation><ArticleIdList><ArticleId IdType="pubmed">28663553</ArticleId><ArticleId IdType="pmc">5491494</ArticleId><ArticleId IdType="doi">10.1038/s41467-017-00062-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold ES, Ling SC, Huelga SC, Lagier-Tourenne C, Polymenidou M, Ditsworth D, et al. ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43. Proc Natl Acad Sci U S A. 2013;110:E736&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pubmed">23382207</ArticleId><ArticleId IdType="pmc">3581922</ArticleId><ArticleId IdType="doi">10.1073/pnas.1222809110</ArticleId></ArticleIdList></Reference><Reference><Citation>Highley JR, Kirby J, Jansweijer JA, Webb PS, Hewamadduma CA, Heath PR, et al. Loss of nuclear TDP-43 in amyotrophic lateral sclerosis (ALS) causes altered expression of splicing machinery and widespread dysregulation of RNA splicing in motor neurones. Neuropathol. Appl. Neurobiol. 2014;40:670&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">24750229</ArticleId><ArticleId IdType="doi">10.1111/nan.12148</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinones-Valdez G, Tran SS, Jun HI, Bahn JH, Yang EW, Zhan L, et al. Regulation of RNA editing by RNA-binding proteins in human cells. Commun Biol. 2019;2:19.</Citation><ArticleIdList><ArticleId IdType="pubmed">30652130</ArticleId><ArticleId IdType="pmc">6331435</ArticleId><ArticleId IdType="doi">10.1038/s42003-018-0271-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Duan Y, Duan G, Wang Q, Zhang K, Deng X, et al. Stress induces dynamic, cytotoxicity-antagonizing TDP-43 nuclear bodies via paraspeckle LncRNA NEAT1-mediated liquid-liquid phase separation. Mol. Cell. 2020;79:443&#x2013;58.e447.</Citation><ArticleIdList><ArticleId IdType="pubmed">32649883</ArticleId><ArticleId IdType="doi">10.1016/j.molcel.2020.06.019</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalfallah Y, Kuta R, Grasmuck C, Prat A, Durham HD, Vande Velde C. TDP-43 regulation of stress granule dynamics in neurodegenerative disease-relevant cell types. Sci. Rep. 2018;8:7551.</Citation><ArticleIdList><ArticleId IdType="pubmed">29765078</ArticleId><ArticleId IdType="pmc">5953947</ArticleId><ArticleId IdType="doi">10.1038/s41598-018-25767-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Konopka A, Whelan DR, Jamali MS, Perri E, Shahheydari H, Toth RP, et al. Impaired NHEJ repair in amyotrophic lateral sclerosis is associated with TDP-43 mutations. Mol. Neurodegener. 2020;15:51.</Citation><ArticleIdList><ArticleId IdType="pubmed">32907630</ArticleId><ArticleId IdType="pmc">7488163</ArticleId><ArticleId IdType="doi">10.1186/s13024-020-00386-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitra J, Guerrero EN, Hegde PM, Liachko NF, Wang H, Vasquez V, et al. Motor neuron disease-associated loss of nuclear TDP-43 is linked to DNA double-strand break repair defects. Proc Natl Acad Sci U S A. 2019;116:4696&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pubmed">30770445</ArticleId><ArticleId IdType="pmc">6410842</ArticleId><ArticleId IdType="doi">10.1073/pnas.1818415116</ArticleId></ArticleIdList></Reference><Reference><Citation>Iguchi Y, Katsuno M, Niwa J, Takagi S, Ishigaki S, Ikenaka K, et al. Loss of TDP-43 causes age-dependent progressive motor neuron degeneration. Brain. 2013;136:1371&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">23449777</ArticleId><ArticleId IdType="doi">10.1093/brain/awt029</ArticleId></ArticleIdList></Reference><Reference><Citation>Babinchak WM, Haider R, Dumm BK, Sarkar P, Surewicz K, Choi JK, et al. The role of liquid-liquid phase separation in aggregation of the TDP-43 low-complexity domain. J. Biol. Chem. 2019;294:6306&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">30814253</ArticleId><ArticleId IdType="pmc">6484124</ArticleId><ArticleId IdType="doi">10.1074/jbc.RA118.007222</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, A, Conicella, AE, Schmidt, HB, Martin, EW, Rhoads, SN, Reeb, AN et al. A single N-terminal phosphomimic disrupts TDP-43 polymerization, phase separation, and RNA splicing. EMBO J. 2018;37:e97452.</Citation></Reference><Reference><Citation>Jiang LL, Xue W, Hong JY, Zhang JT, Li MJ, Yu SN, et al. The N-terminal dimerization is required for TDP-43 splicing activity. Sci. Rep. 2017;7:6196.</Citation><ArticleIdList><ArticleId IdType="pubmed">28733604</ArticleId><ArticleId IdType="pmc">5522446</ArticleId><ArticleId IdType="doi">10.1038/s41598-017-06263-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Kang J, Lim L, Wei Y, Song J. TDP-43 NTD can be induced while CTD is significantly enhanced by ssDNA to undergo liquid-liquid phase separation. Biochem. Biophys. Res. Commun. 2018;499:189&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">29555476</ArticleId><ArticleId IdType="doi">10.1016/j.bbrc.2018.03.121</ArticleId></ArticleIdList></Reference><Reference><Citation>Taslimi A, Vrana JD, Chen D, Borinskaya S, Mayer BJ, Kennedy MJ, et al. An optimized optogenetic clustering tool for probing protein interaction and function. Nat Commun. 2014;5:4925.</Citation><ArticleIdList><ArticleId IdType="pubmed">25233328</ArticleId><ArticleId IdType="doi">10.1038/ncomms5925</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann JR, Gleixner AM, Mauna JC, Gomes E, DeChellis-Marks MR, Needham PG, et al. RNA binding antagonizes neurotoxic phase transitions of TDP-43. Neuron. 2019;102:321&#x2013;38.e328.</Citation><ArticleIdList><ArticleId IdType="pubmed">30826182</ArticleId><ArticleId IdType="pmc">6472983</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2019.01.048</ArticleId></ArticleIdList></Reference><Reference><Citation>Asakawa K, Handa H, Kawakami K. Optogenetic modulation of TDP-43 oligomerization accelerates ALS-related pathologies in the spinal motor neurons. Nat Commun. 2020;11:1004.</Citation><ArticleIdList><ArticleId IdType="pubmed">32081878</ArticleId><ArticleId IdType="pmc">7035286</ArticleId><ArticleId IdType="doi">10.1038/s41467-020-14815-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Polesskaya O, Baranova A, Bui S, Kondratev N, Kananykhina E, Nazarenko O, et al. Optogenetic regulation of transcription. BMC Neurosci. 2018;19:12.</Citation><ArticleIdList><ArticleId IdType="pubmed">29745855</ArticleId><ArticleId IdType="pmc">5998900</ArticleId><ArticleId IdType="doi">10.1186/s12868-018-0411-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Pouzet, S, Banderas, A, Le Bec, M, Lautier, T, Truan, G &amp; Hersen, P. The promise of optogenetics for bioproduction: dynamic control strategies and scale-up instruments. Bioengineering (Basel). 2020;7:151.</Citation></Reference><Reference><Citation>Stockley JH, Evans K, Matthey M, Volbracht K, Agathou S, Mukanowa J, et al. Surpassing light-induced cell damage in vitro with novel cell culture media. Sci. Rep. 2017;7:849.</Citation><ArticleIdList><ArticleId IdType="pubmed">28405003</ArticleId><ArticleId IdType="pmc">5429800</ArticleId><ArticleId IdType="doi">10.1038/s41598-017-00829-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Clackson T, Yang W, Rozamus LW, Hatada M, Amara JF, Rollins CT, et al. Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity. Proc Natl Acad Sci U S A. 1998;95:10437&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">9724721</ArticleId><ArticleId IdType="pmc">27912</ArticleId><ArticleId IdType="doi">10.1073/pnas.95.18.10437</ArticleId></ArticleIdList></Reference><Reference><Citation>Fegan A, White B, Carlson JC, Wagner CR. Chemically controlled protein assembly: techniques and applications. Chem Rev. 2010;110:3315&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">20353181</ArticleId><ArticleId IdType="doi">10.1021/cr8002888</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang W, Rozamus LW, Narula S, Rollins CT, Yuan R, Andrade LJ, et al. Investigating protein-ligand interactions with a mutant FKBP possessing a designed specificity pocket. J. Med. Chem. 2000;43:1135&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">10737745</ArticleId><ArticleId IdType="doi">10.1021/jm9904396</ArticleId></ArticleIdList></Reference><Reference><Citation>Minaki H, Sasaki K, Honda H, Iwaki T. Prion protein oligomers in Creutzfeldt-Jakob disease detected by gel-filtration centrifuge columns. Neuropathology. 2009;29:536&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">19389076</ArticleId><ArticleId IdType="doi">10.1111/j.1440-1789.2009.01007.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanekura K, Ma X, Murphy JT, Zhu LJ, Diwan A, Urano F. IRE1 prevents endoplasmic reticulum membrane permeabilization and cell death under pathological conditions. Sci Signal. 2015;8:ra62.</Citation><ArticleIdList><ArticleId IdType="pubmed">26106220</ArticleId><ArticleId IdType="pmc">4492519</ArticleId><ArticleId IdType="doi">10.1126/scisignal.aaa0341</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin W, Lin Y, Li J, Fenstermaker AG, Way SW, Clayton B, et al. Oligodendrocyte-specific activation of PERK signaling protects mice against experimental autoimmune encephalomyelitis. J. Neurosci. 2013;33:5980&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">23554479</ArticleId><ArticleId IdType="pmc">3654380</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.1636-12.2013</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson BS, Snead D, Lee JJ, McCaffery JM, Shorter J, Gitler AD. TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J. Biol. Chem. 2009;284:20329&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">19465477</ArticleId><ArticleId IdType="pmc">2740458</ArticleId><ArticleId IdType="doi">10.1074/jbc.M109.010264</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinarbasi ES, Cagatay T, Fung HYJ, Li YC, Chook YM, Thomas PJ. Active nuclear import and passive nuclear export are the primary determinants of TDP-43 localization. Sci. Rep. 2018;8:7083.</Citation><ArticleIdList><ArticleId IdType="pubmed">29728608</ArticleId><ArticleId IdType="pmc">5935693</ArticleId><ArticleId IdType="doi">10.1038/s41598-018-25008-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonaka T, Masuda-Suzukake M, Arai T, Hasegawa Y, Akatsu H, Obi T, et al. Prion-like properties of pathological TDP-43 aggregates from diseased brains. Cell Rep. 2013;4:124&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">23831027</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2013.06.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimonaka S, Nonaka T, Suzuki G, Hisanaga S, Hasegawa M. Templated Aggregation of TAR DNA-binding Protein of 43 kDa (TDP-43) by Seeding with TDP-43 Peptide Fibrils. J. Biol. Chem. 2016;291:8896&#x2013;907.</Citation><ArticleIdList><ArticleId IdType="pubmed">26887947</ArticleId><ArticleId IdType="pmc">4861459</ArticleId><ArticleId IdType="doi">10.1074/jbc.M115.713552</ArticleId></ArticleIdList></Reference><Reference><Citation>Li HR, Chiang WC, Chou PC, Wang WJ, Huang JR. TAR DNA-binding protein 43 (TDP-43) liquid-liquid phase separation is mediated by just a few aromatic residues. J. Biol. Chem. 2018;293:6090&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">29511089</ArticleId><ArticleId IdType="pmc">5912450</ArticleId><ArticleId IdType="doi">10.1074/jbc.AC117.001037</ArticleId></ArticleIdList></Reference><Reference><Citation>Maekawa S, Leigh PN, King A, Jones E, Steele JC, Bodi I, et al. TDP-43 is consistently co-localized with ubiquitinated inclusions in sporadic and Guam amyotrophic lateral sclerosis but not in familial amyotrophic lateral sclerosis with and without SOD1 mutations. Neuropathology. 2009;29:672&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">19496940</ArticleId><ArticleId IdType="doi">10.1111/j.1440-1789.2009.01029.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanji K, Zhang HX, Mori F, Kakita A, Takahashi H, Wakabayashi K. p62/sequestosome 1 binds to TDP-43 in brains with frontotemporal lobar degeneration with TDP-43 inclusions. J. Neurosci. Res. 2012;90:2034&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">22674379</ArticleId><ArticleId IdType="doi">10.1002/jnr.23081</ArticleId></ArticleIdList></Reference><Reference><Citation>Fecto F, Yan J, Vemula SP, Liu E, Yang Y, Chen W, et al. SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis. Arch. Neurol. 2011;68:1440&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">22084127</ArticleId><ArticleId IdType="doi">10.1001/archneurol.2011.250</ArticleId></ArticleIdList></Reference><Reference><Citation>Seibenhener ML, Babu JR, Geetha T, Wong HC, Krishna NR, Wooten MW. Sequestosome 1/p62 is a polyubiquitin chain binding protein involved in ubiquitin proteasome degradation. Mol. Cell. Biol. 2004;24:8055&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">15340068</ArticleId><ArticleId IdType="pmc">515032</ArticleId><ArticleId IdType="doi">10.1128/MCB.24.18.8055-8068.2004</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjorkoy G, Lamark T, Johansen T. p62/SQSTM1: a missing link between protein aggregates and the autophagy machinery. Autophagy. 2006;2:138&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16874037</ArticleId><ArticleId IdType="doi">10.4161/auto.2.2.2405</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe S, Inami H, Oiwa K, Murata Y, Sakai S, Komine O, et al. Aggresome formation and liquid-liquid phase separation independently induce cytoplasmic aggregation of TAR DNA-binding protein 43. Cell Death Dis. 2020;11:909.</Citation><ArticleIdList><ArticleId IdType="pubmed">33097688</ArticleId><ArticleId IdType="pmc">7585435</ArticleId><ArticleId IdType="doi">10.1038/s41419-020-03116-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C, Rogelj B, Hortobagyi T, De Vos KJ, Nishimura AL, Sreedharan J, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323:1208&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">19251628</ArticleId><ArticleId IdType="pmc">4516382</ArticleId><ArticleId IdType="doi">10.1126/science.1165942</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald KK, Aulas A, Destroismaisons L, Pickles S, Beleac E, Camu W, et al. TAR DNA-binding protein 43 (TDP-43) regulates stress granule dynamics via differential regulation of G3BP and TIA-1. Hum. Mol. Genet. 2011;20:1400&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">21257637</ArticleId><ArticleId IdType="doi">10.1093/hmg/ddr021</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Nicholson AM, Sarkar M, Messing J, Purice MD, Pottier C, et al. TIA1 mutations in amyotrophic lateral sclerosis and frontotemporal dementia promote phase separation and alter stress granule dynamics. Neuron. 2017;95:808&#x2013;16. e809.</Citation><ArticleIdList><ArticleId IdType="pubmed">28817800</ArticleId><ArticleId IdType="pmc">5576574</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2017.07.025</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosque PJ, Boyer PJ, Mishra P. A 43-kDa TDP-43 species is present in aggregates associated with frontotemporal lobar degeneration. PLoS ONE. 2013;8:e62301.</Citation><ArticleIdList><ArticleId IdType="pubmed">23704877</ArticleId><ArticleId IdType="pmc">3660417</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0062301</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita T, Hideyama T, Hachiga K, Teramoto S, Takano J, Iwata N, et al. A role for calpain-dependent cleavage of TDP-43 in amyotrophic lateral sclerosis pathology. Nat Commun. 2012;3:1307.</Citation><ArticleIdList><ArticleId IdType="pubmed">23250437</ArticleId><ArticleId IdType="doi">10.1038/ncomms2303</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>